2cureX German subsidiary receive contribution for the development of IndiTreat® tests in immuno-oncology

2cureX AB’s German subsidiary 2cureX GmbH (“2cureX”) has received funding from the German Federal Ministry of Education and Research to develop an IndiTreat® test for individualizing immuno-oncological treatment.

2cureX has received a grant of 810,000 EUR from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to adapt the IndiTreat® to individualized immuno-oncology treatment. The project is run in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE). 2cureX is co-financing the project with 378,000 EUR. The project will run until February 2020.

Immuno-oncology has shown tremendous success in a number of solid cancers, and it is one of the fastest growing areas within the oncology area. However, immunotherapy is not a “single silver bullet” as presented by the ASCO (American Society of Clinical Oncology) expert, Michael Sabel*: “Immunotherapy may not be a single silver bullet, but we may need several therapies in combination or one after the other to maximize its efficacy. We also need to develop better pre-treatment tests to find which patients are most likely to benefit and avoid side effects in patients who are not likely to benefit.”

IndiTreat® is a test that uniquely matches the specific patient with and efficacious treatment consisting of an individually tailored combination of approved cancer drugs.

Jürgen Kupper, Managing Director of 2cureX GmbH says: With support from BMBF we have established a strong collaborative team between UKE and 2cureX. Last week this team successfully presented their initial findings to BMBF at a site-visit in our facility in Hamburg. We look forward to expanding the capabilities of IndiTreat® into immuno-oncology”.

* https://www.asco.org/about-asco/press-center/cancer-perspectives/resistance-cancer-immunotherapy-part-ii 

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO;                            Phone: +45 22 11 53 99;         

E-mail: ot@2cureX.com                    URL: www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”). 


Über uns

2cureX hat einen Test namens IndiTreat® (Individual Treatment Design) entwickelt, ein patentiertes Verfahren zur Auswahl des richtigen Medikaments für den richtigen Patienten. IndiTreat® generiert Tausende von 3D-Mikrotumoren, die dem Tumor des Patienten funktionell ähnlich sind. IndiTreat® wählt aus einer großen Auswahl an zugelassenen Krebstherapien die beste Behandlung für den einzelnen Patienten aus. Es wird erwartet, dass IndiTreat® ein Standardwerkzeug in der Behandlungsplanung für Krebspatienten wird. IndiTreat® wird derzeit bei Darm- und Eierstockkrebs klinisch validiert. Das Unternehmen ist an der Nasdaq First North Börse in Stockholm notiert (Symbol „2CUREX“).


Dokumente & Links